

Convenient Syntheses of Phosphinic Analogues of γ -Aminobutyric- and Glutamic Acids¹

M. A. Khomutov^a, A. A. Formanovsky^b, I. V. Mikhura^b, J. Vepsalainen^c, S. N. Kochetkov^a,
D. De Biase^{d, 2}, and A. R. Khomutov^{a, 2}

^aEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, ul. Vavilova 32, Moscow, 119991 Russia

^bShemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences,
ul. Miklukho-Maklaya 16/10, Moscow, 117997 Russia

^cSchool of Pharmacy, University of Eastern Finland, Kuopio, FIN-70211 Finland

^dIstituto Pasteur Italia–Fondazione Cenci Bolognetti, Department of Medico–Surgical Sciences and Biotechnologies
Sapienza University of Rome, Corso della Repubblica 79, Latina, 04100 Italy

Received March 1, 2016; in final form, March 16, 2016

Abstract—Three-steps, one-pot synthesis of 2-amino-4-(hydroxyphosphinyl)butyric acid from dibutyl ester of vinylphosphinic acid was carried out with an overall yield of 66%. 3-Aminopropylphosphinic acid was prepared from allylamine in three steps with an overall yield of 56%. These improved protocols allowed to obtain these commercially unavailable phosphinic analogues of glutamic acid and GABA for testing on potential molecular targets.

Keywords: amino acids, phosphorus analogues, glutamic acid, γ -aminobutyric acid (GABA)

DOI: 10.1134/S1068162016060042

INTRODUCTION

Phosphorus analogues of α -amino acids are compounds in which the carboxyl moiety of the amino acid is substituted with either a phosphonic (Fig. 1a, X = OH) or a phosphinic (Fig. 1a, X = H) group. Representatives of both types of phosphorus analogues of amino acids show broad spectra of biological activity, with the phosphonic ones being the most intensively investigated [1]. In addition to containing an unusual C–P bond (which is rarely occurring also in natural compounds), they present the phosphorus atom in two oxidation forms which affect their biochemical properties. Unlike the doubly-charged tetrahedral phosphonic group, the strongly flattened tetrahedral geometry of the singly-charged phosphinic group is structurally more similar to that of the planar, singly-charged carboxyl group (Fig. 1a). Hence, the aminophosphinic analogues of amino acids were found to be not only inhibitors but also substrates of enzymes of amino acid metabolism [2–5], especially of pyridoxal


5'-phosphate (PLP)-dependent enzymes [2, 6–8], whereas the aminophosphonic acids were only weak inhibitors of the corresponding enzymes.

This is also in line with the observation that cells can uptake aminophosphinic analogues, whereas the phosphonic analogues are unable to penetrate into the cells as such [1]. Indeed, 1-aminoethylphosphinic acid (the phosphinic analogue of Alanine) can be transaminated intracellularly to acetophosphinic acid (the phosphonic analogue of pyruvate), a nanomolar inhibitor of *E. coli* pyruvate dehydrogenase [9, 10]. On the other hand, 1-aminoethylphosphonic acid (the phosphonic analogue of alanine; Ala-*P*), which is a powerful inhibitor of alanine (Ala) racemase and D-Ala:D-Ala ligase [11–13], displays antibiotic activity as inhibitor of cell wall biosynthesis only when delivered intracellularly as Alafosfalin, i.e. an L-Ala-L-Ala-*P* dipeptide [14].

However the family of phosphorus analogues of amino acids should not include only α -amino phosphonates, but also the analogues of aspartic and glutamic acid with the phosphorus-containing group substituting the distal carboxylic moiety. Notably, these compounds were reported to be intermediates (i.e. only occurring in tiny amounts) in the biosynthetic pathway of 2-amino-4-(hydroxymethylphosphinyl)butyric acid (phosphinotricin, PT, Fig. 1b)

¹ The article was translated by the authors.

² Corresponding author: phone: D. De Biase: +39-0773-1757212; fax: +39-0773-1757254; e-mail: daniela.debiase@uniroma1.it; A.R. Khomutov: phone: +7 (499) 135-60-65; e-mail: alexkhom@list.ru. Abbreviations: GABA, 4-aminobutyric acid; GABA-*P*_H, 3-aminopropylphosphinic acid; Glu- γ -*P*_H, 2-amino-4-(hydroxyphosphinyl)butyric acid; AIBN, α, α' -azoisobutyronitrile; PT, phosphinotricin, 2-amino-4-(hydroxymethylphosphinyl)butyric acid.




Scheme 1. Synthesis of Glu- γ - P_H . (i) H_2O /cat. H_2SO_4 /dioxane; (ii) $AcNHCH(COOEt)_2$ /cat. $EtONa$ /dioxane; (iii) $HCl/H_2O/\Delta$; (iv) Dowex50x8 (H^+)/ H_2O .

Given that L-Glu- γ - P_H was reported to be a substrate also of GABA-aminotransferase [8], the phosphinic derivative of GABA, hereafter GABA- P_H , was also synthesized using a convenient protocol. Published three-step synthesis of GABA- P_H [21] comprised the addition of ethyl diethoxymethylene phosphinic acid [22] to acrylonitrile, further Ni-Raney reduction of nitrile and finally, deprotection of aminophosphinite by refluxing in 20% HCl. An overall yield of GABA- P_H was 32% as calculated from starting ethyl diethoxymethylene phosphinic acid [21].

In the present report, GABA- P_H was prepared by an essentially different approach (Scheme 2), con-

sisting in the anti-Markovnikov addition of H_3PO_2 to *N*-(benzyloxycarbonyl)allylamine (V) by refluxing in 80% aq methanol, in the presence of α, α' -azoisobutyronitrile (AIBN) as a catalyst, to yield *N*-Cbz-GABA- P_H . GABA- P_H was obtained after the removal of the *N*-Cbz group by refluxing in 20% HCl and was purified by column chromatography on Dowex 50Wx8 resin (H^+ -form) using 0.5 N HCl as eluent. Subsequent neutralization of GABA- P_H hydrochloride with propylene oxide in EtOH and recrystallization from H_2O /EtOH gave target compound GABA- P_H (VI) with an overall yield of 56% as calculated from allylamine.



Scheme 2. Synthesis of GABA- P_H . (i) $CbzCl/CH_2Cl_2$; (ii) $H_3PO_2/MeOH/H_2O/AIBN/\Delta$; (iii) $HCl/H_2O/\Delta$; (iv) propylene oxide/EtOH.

EXPERIMENTAL

Allylamine, benzyl chloroformate (CbzCl), diethyl acetamidomalonate, 50 wt % hypophosphorous acid solution in H_2O , α, α' -azoisobutyronitrile (AIBN) and Dowex 50Wx8 hydrogen form, 100–200 mesh, were supplied by Aldrich. Dibutyl ester of vinylphosphinic acid was synthesized as described [19]. Diethyl acetamidomalonate was recrystallized from benzene before use.

Ion-exchange chromatography was carried out on Dowex 50Wx8, 100–200 mesh (H^+ -form). Systems for elution are specified in the text. TLC was carried out on Cellulose F_{254} plates (Merck) in the system: *i*-PrOH–25% NH_4OH – H_2O , 7 : 1 : 2 (A) and Kieselgel 60 F_{254} plates (Merck) in: $CHCl_3$ (B). Aminophosphinates were detected on TLC plates with either ammonium

molibdate reagent or by ninhydrin (0.4% in acetone) staining, while Cbz-derivative by UV absorbance.

NMR spectra were registered on a Bruker Avance 400 DRX (Germany) instrument with 400.1 MHz for 1H , 100.6 MHz for ^{13}C and 162 MHz for ^{31}P , either in D_2O with sodium 3-trimethyl-1-propanesulfonate as internal standard and 85% H_3PO_4 as external standard, or in $CDCl_3$ with Me_4Si as internal standard. Chemical shifts are given in ppm, and spin–spin coupling constants in Hz. Melting points were determined in open capillary tubes on Electrothermals Mel-Temp 1202D instrument and are uncorrected.

2-Amino-4-(hydroxyphosphinyl)butyric acid (Glu- γ - P_H) (IV). A solution of 10.8 g (53 mmol) vinylphosphinic acid dibutyl ester and 0.5% aq H_2SO_4 (1.04 g) in dry dioxane (30 mL) was incubated at 20°C for

30 min, evaporated to one-half in vacuo and then diluted with dry dioxane to the initial volume, giving solution (S).

To 11.5 g (53 mmol) of diethyl acetamidomalonate in dry dioxane (80 mL) 2.0 M EtONa/EtOH (3 mL) was added that gave white amorphous gel-like solution, which was evaporated to one-third in vacuo and then diluted with dry dioxane to the initial volume. To this, solution (S) was added and the reaction mixture became slightly cloudy after stirring at 20°C for 35 h under Argon atmosphere. Reaction mixture was evaporated to dryness in vacuo, 20% HCl (200 mL) was added to the residue, refluxed under argon atmosphere for 3 h, evaporated to dryness in vacuo and coevaporated in vacuo with H₂O (3 × 30 mL). This latter residue was dissolved in 15% *i*-PrOH (50 mL) and purified on a Dowex 50Wx8 (H⁺-form) resin (V = 300 mL) by eluting with 15% *i*-PrOH. Fractions containing Glu-γ-P_H (IV) were combined, evaporated to dryness in vacuo, crystallized from H₂O/EtOH and dried in vacuo over P₂O₅ to give (II) (5.86 g, 66%), contaminated with less than 4% (according to ³¹P-NMR) of 2-amino-4-phosphonobutyric acid. Analytical sample (after additional purification on Dowex 50Wx8 resin, elution with 15% *i*-PrOH and subsequent H₂O/EtOH crystallization): mp 216–218°C, dec. (lit.: 193–197°C, dec. [18]; 208–210°C, dec. [20]; 221–222°C, dec. (*L*-isomer) [15]), *R*_f 0.24 (A). ¹H NMR (D₂O) δ: 6.98 (dt, 1 H, *J*_{HP} 523, *J*_{HH} 1.5, P-H), 4.09 (t, 1 H, *J*_{HH} 6.1, CH), 2.22–2.07 (m, 2 H, CH₂P), 1.83–1.61 (m, 2 H, CH₂CH). ¹³C NMR (D₂O) δ: 174.91 s, 56.39 d (*J*_{CP} 16.1), 29.48 d (*J*_{CP} 88.9), 25.35 s. ³¹P NMR (D₂O) δ: 29.67.

***N*-(Benzyloxycarbonyl)allylamine (V).** A solution of 6.88 g (50 mmol) CbzCl in dry CH₂Cl₂ (20 mL) was added within 20 min at +4°C to a stirred solution of 6.38 g (110 mmol) allylamine in dry CH₂Cl₂ (80 mL) and the reaction mixture was stirred at +4°C for 30 min and then for 1 h at 20°C. Reaction mixture was washed with H₂O (3 × 20 mL), 1 M HCl (2 × 20 mL), H₂O (10 mL), 1 M NaHCO₃ (10 mL), H₂O (10 mL), 5 M NaCl (10 mL), dried (Na₂SO₄) and concentrated in vacuo. The residue was dried in vacuo over P₂O₅ to give (V) (9.0 g, 94%) as a viscous oil, *R*_f 0.38 (B). ¹H NMR (CDCl₃) δ: 7.40–7.28 (m, 5 H, C₆H₅), 5.87–5.80 (m, 1 H, CH₂CH), 5.19 (d, 1 H, *J*_{HH} 17, CH₂CH), 5.15–5.08 (m, 3 H, CH₂CH and CH₂C₆H₅), 4.85 (bs, 1 H, NH), 3.80 (m, 2 H, CH₂NH).

3-Aminopropylphosphinic acid (GABA-P_H), (VI). A solution of 1.32 g (7.1 mmol) (V), 50% aq H₃PO₂ (6.06 g) and 0.043 g (0.26 mmol) AIBN in MeOH (20 mL) was refluxed under argon atmosphere for 3 h, diluted with H₂O (30 mL), evaporated to 15 mL in vacuo and extracted with EtOAc (4 × 7 mL). Combined EtOAc extracts were washed with H₂O (3 mL), evaporated to

dryness in vacuo and the residue was coevaporated with H₂O (15 mL) in vacuo. To the final residue 20% HCl (60 mL) was added, refluxed under argon atmosphere for 3 h and extracted with Et₂O (2 × 15 mL). The aqueous layer was evaporated to dryness in vacuo, the residue was dissolved in H₂O (20 mL) and purified on Dowex 50Wx8 (H⁺-form) resin (V = 35 mL) by eluting first with H₂O and then with 0.5 M HCl to isolate pure GABA-P_H. Fractions containing GABA-P_H hydrochloride were combined, evaporated to dryness in vacuo, the residue was dissolved in minimal volume of EtOH and propylene oxide added dropwise until precipitation started. The mixture was allowed to stand at +4°C until complete precipitation, the solid was filtered off, recrystallized from H₂O/EtOH and dried in vacuo over P₂O₅ to give (VI) (0.53 g, 60%), mp 208–211°C (lit.: 209–213°C [22]), *R*_f 0.42 (A). ¹H NMR (D₂O) δ: 6.89 (dt, 1 H, *J*_{HP} 510.7, *J*_{HH} 1.5, P-H), 3.00 (t, 1 H, *J*_{HH} 7.4, CH₂NH₂), 1.85–1.74 (m, 2 H, CH₂CH₂NH₂), 1.59–1.49 (m, 2 H, CH₂P). ¹³C NMR (D₂O) δ: 42.83 d (*J*_{CP} 17.5), 30.99 d (*J*_{CP} 89.8), 22.15 s. ³¹P NMR (D₂O) δ: 28.57.

ACKNOWLEDGMENTS

This work was supported by the Russian Foundation of Basic Research (Grant no. 16-04-01523), Academy of Finland (Agreement no. 292574), the strategic funding from University of Eastern Finland. MAK is gratefully acknowledging the support of the D. Zimin Dynasty Foundation.

REFERENCES

1. Kukhar, V.P. and Hudson, H.R., *Aminophosphonic and Aminophosphinic Acids: Chemistry and Biological Activity*, Wiley, 2000.
2. Khurs, E.N., Osipova, T.I., and Khomutov, R.M., *Bioorg. Khim.*, 1989, vol. 15, pp. 552–555.
3. Laber, B. and Amrhein, N., *Biochem. J.*, 1987, vol. 248, pp. 351–358.
4. Khomutov, R.M., Khurs, E.N., Dzhavahia, V.G., Voinova, T.M., and Ermolinsky, B.S., *Bioorg. Khim.*, 1987, vol. 13, pp. 1422–1424.
5. Biryukov, A.I., Osipova, T.I., and Khomutov, R.M., *FEBS Lett.*, 1978, vol. 91, pp. 246–248.
6. Faleev, N.G., Alferov, K.V., Tsvetkova, M.A., Morozova, E.A., Revtovich, S.V., Khurs, E.N., Vorob'ev, M.M., Phillips, R.S., Demidkina, T.V., and Khomutov, R.M., *Biochim. Biophys. Acta*, 2009, vol. 1794, pp. 1414–1420.
7. Faleev, N.G., Zhukov, Yu.N., Khurs, E.N., Gogoleva, O.I., Barbolina, M.V., Bazhulina, N.P., Belikov, V.M., Demidkina, T.V., and Khomutov, R.M., *Eur. J. Biochem.*, 2000, vol. 267, pp. 6897–6902.
8. Schulz, A., Taggeselle, P., Tripiet, D., and Bartsch, K., *Appl. Environ. Microbiol.*, 1990, vol. 56, pp. 1–6.
9. Laber, B. and Amrhein, N., *Biochem. J.*, 1987, vol. 248, pp. 351–358.

10. Schonbrunn-Hanebeck, E., Laber, B., and Amrhein, N., *Biochemistry*, 1990, vol. 29, pp. 4880–4885.
11. Duncan, K. and Walsh, C.T., *Biochemistry*, 1988, vol. 27, pp. 3709–3714.
12. Badet, B., Inagaki, K., Soda, K., and Walsh, C.T., *Biochemistry*, 1986, vol. 25, pp. 3275–3282.
13. Badet, B. and Walsh, C., *Biochemistry*, 1985, vol. 24, pp. 1333–1341.
14. Allen, J.G., Atherton, F.R., Hall, M.J., Hassall, C.H., Holmes, S.W., Lambert, R.W., Nisbet, L.J., and Ringrose, P.S., *Nature*, 1978, vol. 272, pp. 56–58.
15. Seto, H., Sasaki, T., Imai, S., Tsuruoka, T., Ogawa, H., Satoh, A., Inouye, S., Niida, T., and Otake, N., *J. Antibiot.*, 1983, vol. 36, pp. 96–98.
16. Imai, S., Seto, H., Sasaki, T., Tsuroukai, T., Ogawa, H., Satoh, A., Inouye, S., Niida, T., and Otake, N., *J. Antibiot.*, 1985, vol. 38, pp. 687–690.
17. Selvam, C., Goudet, C., Oueslati, N., Pin, J.P., and Acher, F.C., *J. Med. Chem.*, 2007, vol. 50, pp. 4656–4664.
18. Maier, L. and Rist, G., *Phosph. Sulfur*, 1983, vol. 17, pp. 21–28.
19. Kabachnik, M.I., Zhun-yui Ch., and Tsvetkov E.N., *Zh. Obshch. Khim.*, 1962, vol. 32, pp. 3351–3360.
20. Baylis, E.K., Campbell, C.D., and Dingwall, J.G., *J. Chem. Soc., Perkin Trans. I*, 1984, pp. 2845–2853.
21. Dingwall, J.G., Ehrenfreund, J., and Hall, R.G., *Tetrahedron*, 1989, vol. 45, pp. 3787–3808.
22. Gallagher, M.J. and Honegger, H., *Aust. J. Chem.*, 1980, vol. 33, pp. 287–294.